{"id":404950,"date":"2020-12-23T02:20:39","date_gmt":"2020-12-23T07:20:39","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=404950"},"modified":"2020-12-23T02:20:39","modified_gmt":"2020-12-23T07:20:39","slug":"hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">LUND, Sweden<\/span>, <span class=\"xn-chron\">Dec. 23, 2020<\/span> \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company&#8217;s management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021.<\/p>\n<p>The company presentation will take place virtually <span class=\"xn-chron\">Thursday January 14, 2021<\/span> at <span class=\"xn-chron\">7:30 am (EST)<\/span>\/13:30 (CET).\u00a0<\/p>\n<p>Management will outline Hansa Biopharma&#8217;s proprietary enzyme technology platform as well as provide a status update on Idefirix<sup>\u00ae<\/sup> (imlifidase), which recently obtained conditional approval in the European Union for enabling kidney transplantation in highly sensitized kidney transplant patients. Imlifidase is additionally being evaluated for further use in other transplantation indications as well as investigated in autoimmune indications and as a pretreatment in gene therapy for inactivation of neutralizing antibodies.<\/p>\n<p>Access to the presentation will be available under Events &amp; Presentations on the Investors section of the company website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021394-1&amp;h=1162564903&amp;u=http%3A%2F%2Fwww.hansabiopharma.com%2F&amp;a=www.hansabiopharma.com\" rel=\"nofollow noopener noreferrer\">www.hansabiopharma.com<\/a>.\u00a0<\/p>\n<p>Management will be available for meetings during the J.P. Morgan Conference week. <span class=\"xn-person\">Anne Marie Fields<\/span>, RX Communication, NYC, will coordinate the schedule on behalf of Hansa Biopharma. <span class=\"xn-person\">Anne Marie<\/span> can be reached through <a target=\"_blank\" href=\"mailto:afields@rxir.com\" rel=\"nofollow noopener noreferrer\">afields@rxir.com<\/a>.<\/p>\n<p>In addition to the J.P. Morgan Conference, Hansa Biopharma has been invited to participate in the following conferences during the first half of 2021:<\/p>\n<ul type=\"disc\">\n<li>H.C. Wainwright BioConnect Conference on <span class=\"xn-chron\">Monday January 11, 2021<\/span>, with a presentation available at <span class=\"xn-chron\">6:00 am EST<\/span> \/<span class=\"xn-chron\">12:00 CET<\/span>) on the same day<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>SEB Healthcare Seminar on <span class=\"xn-chron\">Monday January 18, 2021<\/span>, with a presentation at <span class=\"xn-chron\">10:10 am CET<\/span> on the same day<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Vator Swiss-Nordic Healthcare Seminar on <span class=\"xn-chron\">Thursday February 11, 2021<\/span><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Carnegie Nordic Healthcare Seminar on <span class=\"xn-chron\">Tuesday March 9, 2021<\/span><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>Kempen Life Science Conference, <span class=\"xn-chron\">Wednesday May 5, 2021<\/span><\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>RBC Global Healthcare Conference on <span class=\"xn-chron\">Tuesday, May 19, 2021<\/span><\/li>\n<\/ul>\n<p>\n        <b>For further information, please contact:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Klaus Sindahl<\/span>, Head of Investor Relations <br \/>Hansa Biopharma\u00a0<br \/>Mobile: +46 (0) 709-298 269 <br \/>E-mail: <a target=\"_blank\" href=\"mailto:klaus.sindahl@hansabiopharma.com\" rel=\"nofollow noopener noreferrer\">klaus.sindahl@hansabiopharma.com<\/a>\u00a0\u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Katja Margell<\/span><br \/>\n        <br \/>Head of Corporate Communications\u00a0 <br \/>Hansa Biopharma\u00a0<br \/>Mobile: +46 (0) 768-198 326 <br \/>E-mail: <a target=\"_blank\" href=\"mailto:katja.margell@hansabiopharma.com\" rel=\"nofollow noopener noreferrer\">katja.margell@hansabiopharma.com<\/a><\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021394-1&amp;h=628746463&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021394-1&amp;h=3144546808&amp;u=https%3A%2F%2Fnews.cision.com%2Fhansa-biopharma-ab%2Fr%2Fhansa-biopharma-to-present-at-the-39th-annual-j-p--morgan-healthcare-conference%2Cc3261011&amp;a=https%3A%2F%2Fnews.cision.com%2Fhansa-biopharma-ab%2Fr%2Fhansa-biopharma-to-present-at-the-39th-annual-j-p--morgan-healthcare-conference%2Cc3261011\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/hansa-biopharma-ab\/r\/hansa-biopharma-to-present-at-the-39th-annual-j-p&#8211;morgan-healthcare-conference,c3261011<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3021394-1&amp;h=903422089&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F1219%2F3261011%2F1353511.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F1219%2F3261011%2F1353511.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/1219\/3261011\/1353511.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Release<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO32590&amp;sd=2020-12-23\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/hansa-biopharma-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301197989.html\">http:\/\/www.prnewswire.com\/news-releases\/hansa-biopharma-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301197989.html<\/a><\/p>\n<p>SOURCE  Hansa Biopharma AB<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO32590&amp;Transmission_Id=202012230216PR_NEWS_USPR_____IO32590&amp;DateId=20201223\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021 PR Newswire LUND, Sweden, Dec. 23, 2020 \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company&#8217;s management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021. The company presentation will take place virtually Thursday January 14, 2021 at 7:30 am (EST)\/13:30 (CET).\u00a0 Management will outline Hansa Biopharma&#8217;s proprietary enzyme technology platform as well as provide a status update on Idefirix\u00ae (imlifidase), which recently obtained conditional approval in the European Union for enabling kidney transplantation in highly sensitized kidney transplant patients. Imlifidase is additionally being evaluated for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-404950","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021 PR Newswire LUND, Sweden, Dec. 23, 2020 \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company&#8217;s management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021. The company presentation will take place virtually Thursday January 14, 2021 at 7:30 am (EST)\/13:30 (CET).\u00a0 Management will outline Hansa Biopharma&#8217;s proprietary enzyme technology platform as well as provide a status update on Idefirix\u00ae (imlifidase), which recently obtained conditional approval in the European Union for enabling kidney transplantation in highly sensitized kidney transplant patients. Imlifidase is additionally being evaluated for &hellip; Continue reading &quot;Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-23T07:20:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO32590&amp;sd=2020-12-23\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2020-12-23T07:20:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":385,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO32590&amp;sd=2020-12-23\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO32590&amp;sd=2020-12-23\",\"datePublished\":\"2020-12-23T07:20:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO32590&amp;sd=2020-12-23\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO32590&amp;sd=2020-12-23\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021 PR Newswire LUND, Sweden, Dec. 23, 2020 \/PRNewswire\/ &#8212; Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company&#8217;s management team will present at the 39th Annual J.P. Morgan Healthcare Conference 2021. The company presentation will take place virtually Thursday January 14, 2021 at 7:30 am (EST)\/13:30 (CET).\u00a0 Management will outline Hansa Biopharma&#8217;s proprietary enzyme technology platform as well as provide a status update on Idefirix\u00ae (imlifidase), which recently obtained conditional approval in the European Union for enabling kidney transplantation in highly sensitized kidney transplant patients. Imlifidase is additionally being evaluated for &hellip; Continue reading \"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-23T07:20:39+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO32590&amp;sd=2020-12-23","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2020-12-23T07:20:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":385,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO32590&amp;sd=2020-12-23","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO32590&amp;sd=2020-12-23","datePublished":"2020-12-23T07:20:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO32590&amp;sd=2020-12-23","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO32590&amp;sd=2020-12-23"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hansa-biopharma-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=404950"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/404950\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=404950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=404950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=404950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}